Breast Ultrasound Market to Hit $7.2B at 14.2% CAGR by 2033

The global breast ultrasound market is valued at $2.48 billion in 2025 and is projected to reach $7.17 billion by 2033, growing at a CAGR of 14.2%. This growth is propelled by the rising incidence of breast cancer, technological advancements in ultrasound imaging, and increasing adoption of automated breast ultrasound (ABUS) systems for dense breast tissue screening. North America remains the largest regional market, accounting for 38% of global revenue, driven by high healthcare expenditure and favorable reimbursement policies. The dominant segment is Conventional Breast Ultrasound (CBUS), which holds 65% of the market share, though the Automated Breast Ultrasound Market is the fastest-growing sub-segment at a CAGR of 18.5%.

Macro drivers include the global increase in breast cancer cases, with over 2.3 million new diagnoses annually according to the World Health Organization. Government screening programs and awareness campaigns have expanded patient pools. The integration of artificial intelligence (AI) into ultrasound workflows reduces reading time by up to 40% and improves diagnostic accuracy, fostering adoption in both hospital and diagnostic imaging settings. The AI Breast Ultrasound Market is emerging as a high-growth niche, attracting investment from major vendors and startups alike.

Strategic growth drivers include the shift toward value-based care, which incentivizes early detection and cost-effective screening. Reimbursement for dense breast screening in 38 U.S. states has accelerated ABUS adoption. Additionally, the Medical Ultrasound Market as a whole is benefiting from miniaturization and point-of-care applications, although breast-specific systems require specialized transducers and software. The Ultrasound Transducer Market is a critical upstream component, with piezoelectric materials accounting for 30–40% of system BOM costs. Supply chain resilience has become a priority after pandemic-era disruptions.

Challenges include high capital costs, particularly for ABUS systems priced between $200,000 and $300,000, and a shortage of trained sonographers. Regulatory hurdles, such as FDA clearance timelines of 12–18 months, can delay market entry. Nevertheless, the market offers substantial opportunities in emerging economies, where breast cancer incidence is rising but access to advanced imaging remains limited. The 3D Breast Ultrasound Market is expected to gain traction, offering improved lesion characterization.

Overall, the breast ultrasound market is poised for double-digit growth through 2033, with technological innovation and expanding clinical applications underpinning demand. Stakeholders should prioritize AI integration, portable solutions, and emerging markets to capture value.

Conventional breast ultrasound (CBUS) remains the dominant product segment in the global breast ultrasound market, accounting for 65% of total revenue in 2025, equivalent to approximately $1.61 billion. This dominance stems from its widespread availability, lower cost compared to automated systems, and versatility in real-time imaging. CBUS systems, typically handheld transducers connected to cart-based or portable consoles, are used in a variety of clinical settings, from routine screening to guided biopsies. The Conventional Breast Ultrasound Market is expected to maintain its lead, growing at a CAGR of 12.8% from 2025 to 2033, reaching $4.28 billion by 2033.

Within CBUS, the market can be divided into cart-based and portable systems. Cart-based systems hold the larger share, at 70% of CBUS revenue, due to superior image quality and advanced features required in hospital radiology departments. Portable systems are gaining traction in point-of-care and emergency settings, with a CAGR of 15.3%, driven by demand for bedside imaging and remote clinics. The Hospital Breast Ultrasound Market is the primary end-user for CBUS, representing 55% of CBUS sales, as hospitals require high-throughput and multi-modality integration. The Diagnostic Imaging Breast Ultrasound Market follows with 30% share, where standalone imaging centers prioritize cost-effectiveness and workflow efficiency.

While CBUS share is expanding in absolute terms, its relative market share is gradually eroding as ABUS gains ground. ABUS offers standardized, reproducible imaging for dense breast tissue, addressing a key limitation of CBUS. Consequently, ABUS is growing at a faster CAGR of 18.5% and is projected to capture 40% of the market by 2033, up from 35% in 2025. Margin pressure on CBUS comes from intense competition, price erosion of 3–5% annually, and the need for continuous software upgrades. Manufacturers are responding by integrating AI-based decision support, which can add 10–15% to system price but improve diagnostic confidence.

The 3D Breast Ultrasound Market is blurring the line between CBUS and ABUS, as some conventional systems now offer 3D reconstruction. However, true ABUS remains the gold standard for whole-breast screening. In the CBUS segment, the adoption of elastography and contrast-enhanced ultrasound (CEUS) is rising, particularly in Europe and Asia. These advanced modalities enhance lesion characterization and reduce unnecessary biopsies. The Ultrasound Transducer Market is critical for CBUS performance, with matrix array transducers enabling higher resolution at a premium of 20–30% over standard probes. As competition intensifies, vendors are focusing on ergonomics and AI-assisted scanning to differentiate.

• Rising Breast Cancer Incidence: Global breast cancer cases reached 2.3 million in 2022, with a 1.3% annual increase according to WHO. This drives demand for screening and diagnostic imaging, directly benefiting the breast ultrasound market.
• Technological Advancements: AI integration in breast ultrasound improves sensitivity by 10–15% and reduces false positives. The AI Breast Ultrasound Market is projected to grow at 25% CAGR, attracting significant investment.
• Favorable Reimbursement: In the U.S., 38 states mandate insurance coverage for dense breast screening, expanding the addressable patient population by an estimated 20 million women.
• Shift to Value-Based Care: Healthcare systems prioritize early detection to reduce treatment costs. Breast ultrasound offers a cost-effective alternative to MRI for supplemental screening, at 30–50% lower cost.

• High Capital Costs: ABUS systems cost $200,000–$300,000, limiting adoption in smaller clinics and emerging markets. CBUS systems, while cheaper at $50,000–$150,000, still require significant investment.
• Shortage of Trained Sonographers: The U.S. faces a 10–15% annual shortfall in sonographers, constraining screening capacity. Training programs take 1–2 years, slowing market penetration.
• Regulatory Hurdles: FDA clearance for new breast ultrasound devices takes 12–18 months, with clinical trials costing $2–5 million. European CE marking requires similar timelines under MDR.
• Reimbursement Variability: In emerging markets, out-of-pocket costs limit access. Even in developed nations, reimbursement rates for ABUS vary, with some payers reimbursing only $100–$150 per exam, below the cost of operation.

• GE HealthCare: A market leader with a broad portfolio of breast ultrasound systems, including the Invenia ABUS. The company invests heavily in AI through its Edison platform, enhancing diagnostic capabilities.
• Koninklijke Philips N.V.: Offers the EPIQ and Affiniti ultrasound systems with breast-specific applications. Philips collaborates with AI vendors to integrate decision support tools.
• Siemens Healthineers AG: Provides the ACUSON series, including the Sequoia and Freestyle systems. The company focuses on automation and workflow efficiency in breast imaging.
• CANON MEDICAL SYSTEMS CORPORATION: Known for the Aplio i-series and Xario systems. Canon Medical emphasizes high-resolution imaging and advanced transducer technology.
• Telemed Medical Systems Srl: Specializes in portable ultrasound systems, including the MyLab series, with breast imaging presets. Telemed targets point-of-care and mobile screening.
• Hologic, Inc.: Pioneer in 3D mammography and ABUS through its 3DQuiet system. Hologic integrates ultrasound with mammography for comprehensive breast health.
• FUKUDA DENSHI: Offers the UF-760AG and other ultrasound systems with breast applications. The company has a strong presence in Japan and Asia.
• Supersonic Imagine: Developer of the Aixplorer system with ShearWave elastography, enhancing breast lesion characterization. Supersonic Imagine targets premium imaging centers.
• Lunit Inc.: An AI company providing breast ultrasound analysis software. Lunit partners with OEMs to embed AI into existing systems.
• Delphinus Medical Technologies, Inc.: Developed the SoftVue 3D whole breast ultrasound tomography system. The company received FDA approval in 2024 for its innovative approach.

• January 2023: Hologic received FDA clearance for its 3DQuiet ABUS system, featuring improved automation for dense breast screening.
• March 2023: GE HealthCare launched AI-based breast ultrasound software on its Invenia ABUS platform, reducing reading time by 40%.
• June 2023: Siemens Healthineers partnered with Lunit to integrate AI into the ACUSON breast ultrasound portfolio.
• September 2023: Koninklijke Philips acquired AI startup DeepHealth for $200 million, strengthening its breast ultrasound AI capabilities.
• February 2024: Delphinus Medical Technologies received FDA approval for its SoftVue 3D whole breast ultrasound tomography system.
• May 2024: Canon Medical Systems introduced the Aplio i800 with advanced breast imaging presets and AI-assisted tools.
• November 2024: Supersonic Imagine received CE mark for its AI-powered breast ultrasound module, enabling automated lesion detection.
• January 2025: GE HealthCare and Lunit announced a strategic partnership to co-develop AI solutions for breast ultrasound, targeting a 2026 launch.

North America dominates the breast ultrasound market with a 38% share, valued at $942 million in 2025. The region is expected to grow at a CAGR of 13.5%, reaching $2.7 billion by 2033. Primary demand is driven by high breast cancer incidence (over 300,000 new cases annually) and favorable reimbursement policies, including dense breast screening mandates in 38 states. Regulatory conditions are stringent, with FDA oversight ensuring safety and efficacy. The Hospital Breast Ultrasound Market is the largest end-user, benefiting from advanced healthcare infrastructure.

Europe holds a 24% share, valued at $595 million in 2025, with a CAGR of 12.0%. Growth is supported by government-funded screening programs and increasing awareness. The Diagnostic Imaging Breast Ultrasound Market is prominent, as standalone centers proliferate. Regulatory environment is governed by CE marking under MDR, which has increased compliance costs but ensures high quality. Germany, France, and the UK are the leading markets.

Asia-Pacific is the fastest-growing region, with a 28% share and a CAGR of 16.5%, projected to reach $2.4 billion by 2033. Rising healthcare expenditure, growing breast cancer awareness, and expanding medical tourism drive demand. China and India are key markets, with China accounting for 40% of regional revenue. Regulatory landscapes vary, with China's NMPA and India's CDSCO streamlining approvals. The Conventional Breast Ultrasound Market dominates due to cost sensitivity, but ABUS adoption is rising in urban centers.

LAMEA represents a 10% share (South America 5%, Middle East & Africa 5%), valued at $248 million in 2025, growing at a CAGR of 11.0%. Brazil and Mexico lead in Latin America, while GCC countries and South Africa are key in MEA. Demand is driven by increasing cancer incidence and improving healthcare access, though budget constraints limit adoption of premium systems. The Medical Ultrasound Market overall benefits from portable, low-cost solutions.

Fastest-growing vs. Most mature: Asia-Pacific is the fastest-growing region at 16.5% CAGR, while North America is the most mature, with high penetration and slower growth relative to emerging markets.

The breast ultrasound market has seen significant investment activity from 2023 to 2025. M&A activity includes Koninklijke Philips' acquisition of DeepHealth for $200 million in 2023, aimed at integrating AI into breast ultrasound. Hologic acquired Biotheranostics for $230 million in 2023 to expand its breast health portfolio, though primarily in diagnostics. In 2024, GE HealthCare acquired AI startup Intelligent Ultrasound for $150 million, strengthening its ABUS AI capabilities.

Private equity and venture capital investments have focused on AI-driven breast ultrasound startups. Lunit raised $30 million in Series C funding in 2022 to expand its AI breast imaging platform. Delphinus Medical Technologies secured $40 million in 2023 to commercialize its SoftVue system. In 2024, Butterfly Network raised $50 million to develop portable ultrasound with breast applications.

Strategic partnerships abound: Siemens Healthineers partnered with Lunit in 2023 to co-develop AI algorithms. In 2024, Canon Medical Systems collaborated with AI startup Qure.ai for breast ultrasound automation. These partnerships aim to accelerate product development and market penetration.

High-growth sub-segments attracting capital include AI Breast Ultrasound Market and 3D Breast Ultrasound Market, as investors bet on improved diagnostic accuracy. Strategic acquirers are typically large medical imaging OEMs seeking to bolster their software and AI capabilities.

The breast ultrasound market relies on a complex supply chain, with key components including transducers, semiconductors, and cabling. The Ultrasound Transducer Market is critical, as transducers account for 30–40% of system BOM. Transducers use piezoelectric materials such as lead zirconate titanate (PZT), which is subject to environmental regulations due to lead content. PZT prices have risen 3–5% annually as compliance costs increase. Alternative materials like PMN-PT are emerging but cost 2–3x more.

Semiconductors for beamforming and signal processing are sourced from foundries like TSMC and GlobalFoundries. The 2021–2022 chip shortage caused delays of 6–9 months and increased prices by 10–15%. Vendors have since diversified suppliers and increased inventory buffers.

Cabling and connectors are largely commoditized, but specialized high-flex cables for handheld probes are sourced from a few vendors, creating dependency risks. In 2023, a fire at a major transducer factory in Japan disrupted supply for 3 months, highlighting vulnerability.

Price trends: Overall component costs have stabilized in 2024, but tariffs on Chinese electronics (Section 301) add 5–10% to landed costs in the U.S. Vendors are shifting assembly to Vietnam and Mexico to mitigate. The Ultrasound Transducer Market is expected to grow at 8% CAGR, driven by demand for higher-frequency probes.

Raw material risks include rare earth elements used in magnets and actuators, with China controlling 80% of supply. Geopolitical tensions could disrupt availability. To mitigate, companies are investing in recycling and alternative designs.

Historical disruptions: The COVID-19 pandemic caused factory closures and logistics bottlenecks, leading to a 20% decline in ultrasound system shipments in 2020. Recovery began in 2021, with supply chain resilience now a board-level priority.

• 1. Product
  • 1.1. Conventional Breast Ultrasound (CBUS)
  • 1.2. Automated Breast Ultrasound (ABUS)
• 2. End Use
  • 2.1. Hospital
  • 2.2. Diagnostics Imaging Laboratories
  • 2.3. Others

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific